drugset / Trial / NCT06505031
A Study of TAK-861 in People With Narcolepsy Type 1
RandomizedParallel-groupDouble-blindTreatment
Summary
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.
Timeline
- Start
- 2024-10-08
- Primary completion
- 2025-06-04
- Completion
- 2025-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | oveporexton | Small molecule | 2 mg | Oral |